ulviprubart

Ulviprubart is a first-in-class, humanized, afucosylated monoclonal antibody targeting killer cell lectin-like receptor G1 (KLRG1). It is designed to selectively deplete highly cytotoxic T cells while sparing naïve, regulatory, and central memory T cells. The drug is being developed primarily for the treatment of inclusion body myositis (IBM), a rare autoimmune muscle disease characterized by progressive muscle weakness and atrophy. Ulviprubart has also been investigated in T cell large granular lymphocytic leukemia (T-LGLL) and mature T cell malignancies. Both the US FDA and EMA have granted orphan drug designation to ulviprubart for IBM. Its mechanism of action involves antagonism of KLRG1 on cytotoxic immune cells, leading to their selective depletion through antibody-dependent cellular cytotoxicity[1][3][4][5][6][7][8].

Other names

anti-KLRG1 antibodyanti-KLRG-1 antibodyanti-KLRG 1 antibody